Abcellera Biologics Inc (ABCL)

$4.35 -0.12 (-2.68%)
Market Cap 1.34B
Revenue (ttm) 28.83M
Net Income (ttm) -162.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -564.90%
Debt to Equity Ratio 0.00
Volume 3,133,700
Avg Vol 5,493,656
Day's Range N/A - N/A
Shares Out 298.83M
Stochastic %K 60%
Beta 0.64
Analysts Strong Sell
Price Target $9.29

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 West 4th Ave, Vancouver, Canada
Ed_Ng
Ed_Ng Sep. 16 at 1:53 PM
$ABCL lol pump and dump
1 · Reply
Ed_Ng
Ed_Ng Sep. 16 at 1:36 PM
$ABCL back down to 4.2 by EOD
0 · Reply
sydzek
sydzek Sep. 16 at 12:57 PM
$ABCL Confident.
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 16 at 12:45 PM
$ABCL
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 16 at 11:39 AM
$ABCL 👀 Their days are numbered 🤫
0 · Reply
BillionerOfKing
BillionerOfKing Sep. 16 at 10:01 AM
$ABCL Current Stock Price: $4.34 Contracts to trade: $5 ABCL Sep 19 2025 Call Entry: $0.09 Exit: $0.14 ROI: 57% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BillionerOfKing
BillionerOfKing Sep. 16 at 9:35 AM
$ABCL Current Stock Price: $4.34 Contracts to trade: $5 ABCL Sep 19 2025 Call Entry: $0.09 Exit: $0.17 ROI: 84% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BarrenWuffet007
BarrenWuffet007 Sep. 16 at 6:14 AM
$ABCL down 4% in Europe
1 · Reply
Plutten1973
Plutten1973 Sep. 16 at 4:30 AM
$ABCL Shorters still playing alot over 50% short volume
0 · Reply
Ed_Ng
Ed_Ng Sep. 15 at 10:38 PM
$ABCL no one was accumulating. No volume
0 · Reply
Latest News on ABCL
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 6 days ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 20 days ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 4 weeks ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:48 PM EDT - 5 weeks ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 5 weeks ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 2 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 3 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 4 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 4 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 4 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:33 PM EDT - 4 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 4 months ago

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 4 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 6 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:26 PM EST - 7 months ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 7 months ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 7 months ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 8 months ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 8 months ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics: Still A Concept Stock

Dec 23, 2024, 4:39 PM EST - 9 months ago

AbCellera Biologics: Still A Concept Stock

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 10 months ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 11 months ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 7:22 PM EST - 11 months ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 11 months ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 11 months ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera: A Platform To Pipeline Transition

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera: A Waiting Game With High Uncertainty

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

May 7, 2024, 11:00 PM EDT - 1 year ago

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2024 Business Results

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 1, 2024, 9:00 AM EDT - 1 year ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 8, 2024, 12:05 PM EDT - 1 year ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 3, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 19, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

Mar 11, 2024, 9:00 AM EDT - 1 year ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Mar 5, 2024, 4:30 PM EST - 1 year ago

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

AbCellera Announces Resignation of Board Member

Feb 23, 2024, 4:30 PM EST - 1 year ago

AbCellera Announces Resignation of Board Member

AbCellera to Present at Upcoming Investor Conferences in March

Feb 22, 2024, 8:15 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in March

AbCellera Biologics Inc. (ABCL) Q4 2023 Earnings Call Transcript

Feb 20, 2024, 11:45 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q4 2023 Earnings Call Transcript

AbCellera Reports Full Year 2023 Business Results

Feb 20, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2023 Business Results

AbCellera to Report Full Year 2023 Financial Results on February 20, 2024

Jan 23, 2024, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2023 Financial Results on February 20, 2024

Ed_Ng
Ed_Ng Sep. 16 at 1:53 PM
$ABCL lol pump and dump
1 · Reply
Ed_Ng
Ed_Ng Sep. 16 at 1:36 PM
$ABCL back down to 4.2 by EOD
0 · Reply
sydzek
sydzek Sep. 16 at 12:57 PM
$ABCL Confident.
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 16 at 12:45 PM
$ABCL
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 16 at 11:39 AM
$ABCL 👀 Their days are numbered 🤫
0 · Reply
BillionerOfKing
BillionerOfKing Sep. 16 at 10:01 AM
$ABCL Current Stock Price: $4.34 Contracts to trade: $5 ABCL Sep 19 2025 Call Entry: $0.09 Exit: $0.14 ROI: 57% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BillionerOfKing
BillionerOfKing Sep. 16 at 9:35 AM
$ABCL Current Stock Price: $4.34 Contracts to trade: $5 ABCL Sep 19 2025 Call Entry: $0.09 Exit: $0.17 ROI: 84% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BarrenWuffet007
BarrenWuffet007 Sep. 16 at 6:14 AM
$ABCL down 4% in Europe
1 · Reply
Plutten1973
Plutten1973 Sep. 16 at 4:30 AM
$ABCL Shorters still playing alot over 50% short volume
0 · Reply
Ed_Ng
Ed_Ng Sep. 15 at 10:38 PM
$ABCL no one was accumulating. No volume
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 15 at 10:29 PM
$ABCL TD Cowen reiterates buy rating on $ABCL!
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 15 at 10:28 PM
$ABCL $ABCL this is a triangle within a triangle... everything is a triangle. chill!
0 · Reply
DeMampCamp
DeMampCamp Sep. 15 at 7:51 PM
$ABCL They dropped it early this morning and have kept it pinned all day, wonder who's accumulating
0 · Reply
Determinedstocks
Determinedstocks Sep. 15 at 5:36 PM
$PRME $QSI $NTLA $ABCL Please, somebody, tell me how this makes any sense? Is this what some of you voted for? Because this is batshit backwards in terms of heath care outcomes and US competitiveness. Bonkers! https://www.nytimes.com/2025/09/14/magazine/cancer-research-grants-funds-trump.html
1 · Reply
estatebuyersmia
estatebuyersmia Sep. 15 at 5:25 PM
$ABCL WITHOUT VOLUME THIS STOCK IS RANGE BOUND....
0 · Reply
Andyfeliciano6
Andyfeliciano6 Sep. 15 at 5:12 PM
$ABCL Accumulating more as we drop. LT Hold
0 · Reply
Plutten1973
Plutten1973 Sep. 15 at 4:33 PM
$ABCL Today i was sure we would go up ,but not its good we have a normal Abcellera day feels strange if it continues up to fast 😅😅
0 · Reply
Stockfinesser20
Stockfinesser20 Sep. 15 at 4:05 PM
$ABCL https://finance.yahoo.com/news/td-cowen-reiterates-buy-rating-121711739.html
0 · Reply
Ed_Ng
Ed_Ng Sep. 15 at 3:52 PM
$ABCL garbage 🗑️
0 · Reply
DeMampCamp
DeMampCamp Sep. 15 at 2:20 PM
$ABCL Over 300,000 traded in PM with really zero overall movement and then the market opens and zero buying, just constant market sell orders on the bid. Those looking for another entry to average down/up, here you go!
0 · Reply
DeMampCamp
DeMampCamp Sep. 15 at 1:55 PM
$ABCL Headed for the 50 day sma at $4.38 and bounce?
1 · Reply
BarrenWuffet007
BarrenWuffet007 Sep. 15 at 1:35 PM
$ABCL https://www.fiercebiotech.com/biotech/trump-admin-mulls-severe-restrictions-us-pharmas-securing-chinese-meds-nyt
0 · Reply